Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Unresectable or Metastatic Melanoma
NCT03149029Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2017
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, trametinib and dabrafenib + trametinib in melanoma (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Rate of Clinical Benefit at 6 months. Started Nov 2017; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03149029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149029.